Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study

2019 ◽  
Vol 26 (9) ◽  
pp. 1200-1204 ◽  
Author(s):  
J. P. Cuello ◽  
M. L. Martínez Ginés ◽  
J. Kuhle ◽  
J. M. García Domínguez ◽  
A. Lozano Ros ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cohort Study ◽  
Prospective Cohort Study ◽  
Light Chain ◽  
Prospective Cohort ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
Multiple Sclerosis Patients

Validation of CSF free light chain in diagnosis and prognosis of multiple sclerosis and clinically isolated syndrome: prospective cohort study in Buenos Aires

2018 ◽  
Vol 266 (1) ◽  
pp. 112-118 ◽  
Author(s):  
María Soledad Sáez ◽  
Juan Ignacio Rojas ◽  
María Victoria Lorenzón ◽  
Francisco Sánchez ◽  
Liliana Patrucco ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cohort Study ◽  
Prospective Cohort Study ◽  
Light Chain ◽  
Prospective Cohort ◽  
Buenos Aires ◽  
Clinically Isolated Syndrome ◽  
Free Light Chain ◽  
Diagnosis And Prognosis

Neurofilament Light Chain Levels Are Associated with Disease Activity Determined by No Evident Disease Activity in Multiple Sclerosis Patients

2021 ◽  
pp. 1-8
Author(s):  
Jarmila Szilasiová ◽  
Jaroslav Rosenberger ◽  
Miriam Fedičová ◽  
Pavol Mikula ◽  
Peter Urban ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Magnetic Resonance ◽  
Disease Activity ◽  
Sensitivity And Specificity ◽  
Light Chain ◽  
Operating Characteristics ◽  
Disability Score ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
Multiple Sclerosis Patients

<b><i>Introduction:</i></b> There is a need for blood biomarkers of disease activity in multiple sclerosis (MS). The aim of the study was to assess the relationship between plasma neurofilament light chain (pNfL) and disease activity as defined by the concept three-domain no evident disease activity (NEDA-3). <b><i>Methods:</i></b> Levels of pNfL (SIMOA) were examined in 159 MS patients and analyzed in relationship to NEDA-3 status (absence of relapse, disability score worsening, and brain magnetic resonance activity) during the last 12 months. The accuracy of the proposed model was evaluated by calculating the area under the receiver operating characteristics (ROC) curve. From the pNfL cutoff, we evaluated the NEDA-NfL status (no relapse, no Expanded Disability Status Scale [EDSS] worsening, and pNfL below the cutoff value). <b><i>Results:</i></b> Levels of pNfL were significantly higher in MS patients than in healthy controls (<i>p</i> &#x3c;  0.001). From a total of 159 patients, 80 (50.3%) achieved NEDA-3 status, while 79 (49.7%) patients showed evident disease activity (EDA) status. pNfL were significantly lower in the NEDA-3 group than in the EDA group (pNfL mean 7.06 pg/mL [standard deviation (SD) 2.37] vs. pNfL mean 13.04 pg/mL [SD 7.07]) (<i>p</i> &#x3c; 0.001). ROC analysis showed that pNfL predicts NEDA-3 status (sensitivity and specificity were 80.5 and 72.7%, respectively, <i>p</i> &#x3c; 0.001), and NEDA-NfL predicts NEDA-3 status (sensitivity and specificity were 97.1 and 82.9%, respectively, <i>p</i> &#x3c; 0.001). <b><i>Conclusion:</i></b> The results show that pNfL levels are a useful biomarker of disease activity determined by NEDA status in patients with MS and could be an alternative to brain magnetic resonance investigation.

Longitudinal serum neurofilament light chain (sNfL) concentration relates to cognitive function in multiple sclerosis patients

2020 ◽  
Vol 267 (8) ◽  
pp. 2245-2251 ◽  
Author(s):  
Flavia Mattioli ◽  
F. Bellomi ◽  
C. Stampatori ◽  
S. Mariotto ◽  
S. Ferrari ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cognitive Function ◽  
Light Chain ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
Multiple Sclerosis Patients
Sign in / Sign up

Export Citation Format

Share Document